In this episode of "From Our Neurons to Yours," we're taking a deep dive into the neuroscience of obsessive-compulsive disorder (OCD) and the recent discovery that the anesthetic ketamine can give patients a week-long "vacation" from the disorder after just one dose.

Join us as we chat with Dr. Carolyn Rodriguez, a leading expert in the field, who led the first clinical trial of Ketamine for patients with OCD. She sheds light on what OCD truly is, breaking down the misconceptions and revealing the reality of this serious condition.

Dr. Rodriguez, a professor of psychiatry at Stanford Medicine, discusses her research on ketamine for OCD, current hypotheses about how it works in the brain, and her approach to developing safer treatments. Listeners are encouraged to seek help if they or a loved one are struggling with OCD.

Learn more:

Rodriguez's OCD Research Lab (website)
Rodriguez at the World Economic Forum (video - WEF)
International OCD Foundation (IOCDF) (website)
Rodriguez pioneers VR therapy for patients with hoarding disorder (video - Stanford Medicine)
The rebirth of psychedelic medicine (article - Wu Tsai Neuro)
Researcher investigates hallucinogen as potential OCD treatment (article - Stanford Medicine)

Episode credits:

This episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute.

Thanks for listening! Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

OCD & Ketamine | Carolyn Rodriguez

From Our Neurons to Yours